Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentoxifylline + ursodeoxycholic acid is a combination therapy that has been studied for its protective effects on liver tissue, particularly in radiation-induced liver injury and non-alcoholic fatty liver disease. This combination works through multiple complementary mechanisms: pentoxifylline exhibits hemorheological, anti-oxidative, and anti-inflammatory properties, while ursodeoxycholic acid reduces potentially toxic hydrophobic bile acids and has anti-inflammatory and anti-apoptotic effects. Together, they have been shown to significantly reduce the extent and incidence of focal radiation-induced liver injury (fRILI) when administered post-therapeutically. The combination has also demonstrated effectiveness in decreasing serum inflammatory cytokines like IL-8 and TNF-α in non-alcoholic fatty liver cases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentoxifylline + ursodeoxycholic acid.